Continuous and prolonged intravenous β-lactam dosing: Implications for the clinical laboratory

Clinical Microbiology Reviews

Volumn 29, Issue 4, 2016, Pages 750-772

  Grupper, Mordechai ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEMASE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; DORIPENEM; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; PENICILLIN G DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TEMOCILLIN; TIMENTIN; ANTIINFECTIVE AGENT; BETA LACTAM;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL LABORATORY; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG APPROVAL; DRUG MONITORING; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; LABORATORY DIAGNOSIS; META ANALYSIS (TOPIC); MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; BACTERIAL INFECTIONS; BACTERIUM; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; PROCEDURES; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BETA-LACTAMS; HUMANS; INFUSIONS, INTRAVENOUS; TREATMENT OUTCOME;

EID: 84978890842     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00022-16     Document Type: Review

References (142)

1. IDSA. 2011. IDSA: facts about antibiotic resistance. http://www.idsociety.org/AR_Facts/#. Accessed 30 December 2015.
2. WHO. 2014. Antimicrobial resistance: global report on surveillance 2014. http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1. Accessed 30 December 2015.
3. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48: 1-12. http://dx.doi.org/10.1086/595011.
4. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. 2013. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 56: 272-282. http://dx.doi.org/10.1093/cid/cis857.
5. Felton TW, Hope WW, Lomaestro BM, Butterfield JM, Kwa AL, Drusano GL, Lodise TP. 2012. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. Antimicrob Agents Chemother 56: 4087-4094. http://dx.doi.org/10.1128/AAC.00521-12.
6. Georges B, Conil JM, Ruiz S, Seguin T, Cougot P, Fourcade O, Houin G, Saivin S. 2012. Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations. Br J Clin Pharmacol 73: 588-596. http://dx.doi.org/10.1111/j.1365-2125.2011.04117.x.
7. MacGowan A. 2011. Revisiting beta-lactams-PK/PD improves dosing of old antibiotics. Curr Opin Pharmacol 11: 470-476. http://dx.doi.org /10.1016/j.coph.2011.07.006.
8. Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, Sörgel F, Jones RN, Drusano GL, Bertino JS, Jr. 2010. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis 68: 251-258. http://dx.doi.org/10.1016/j.diagmicrobio.2010.06.012.
9. Landersdorfer CB, Kirkpatrick CM, Kinzig-Schippers M, Bulitta JB, Holzgrabe U, Drusano GL, Sörgel F. 2007. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin. Antimicrob Agents Chemother 51: 3290-3297. http://dx.doi.org/10.1128/AAC.01410-06.
10. Drusano GL. 2007. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 45(Suppl 1):S89-S95. http://dx.doi.org/10.1086/518137.
11. Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL. 2014. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14: 498-509. http://dx.doi.org/10.1016/S1473-3099(14)70036-2.
12. Society for Healthcare Epidemiology of America, Infectious Diseases Society of America, Pediatric Infectious Diseases Society. 2012. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 33: 322-327. http://dx.doi.org/10.1086/665010.
13. Turnidge JD. 1998. The pharmacodynamics of beta-lactams. Clin Infect Dis 27: 10-22. http://dx.doi.org/10.1086/514622.
14. Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol 2: 289-300. http://dx.doi.org /10.1038/nrmicro862.
15. Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP. 2007. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn Microbiol Infect Dis 57: 153-161. http://dx.doi.org/10.1016/j.diagmicrobio.2006.06.014.
16. De Waele J, Carlier M, Hoste E, Depuydt P, Decruyenaere J, Wallis SC, Lipman J, Roberts JA. 2014. Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis. Minerva Anestesiol 80: 1302-1309.
17. Lipš M, Siller M, Strojil J, Urbánek K, Balík M, Suchánková H. 2014. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. Int J Antimicrob Agents 44: 358-362. http://dx.doi.org/10.1016/j.ijantimicag.2014.05.011.
18. Yusuf E, Spapen H, Piérard D. 2014. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review. J Crit Care 29: 1089-1095. http://dx.doi.org/10.1016/j.jcrc.2014.07.033.
19. Roberts JA, Lipman J, Blot S, Rello J. 2008. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care 14:390-396. http://dx.doi.org/10.1097/MCC.0b013e3283021b3a.
20. Eagle HR, Fleischman R, Levy M. 1953. "Continuous" vs. "discontinuous" therapy with penicillin: the effect of the interval between injections on therapeutic efficacy. N Engl J Med 8: 481-488.
21. Eagle HR, Fleischman R, Musselman AD. 1950. Effect of schedule of administration on the therapeutic efficacy of penicillin: importance of the aggregate time penicillin remains at effectively bactericidal levels. Am J Med 9:280-299. http://dx.doi.org/10.1016/0002-9343(50)90425-6.
22. Schmidt LH, Walley A, Larson RD. 1949. The influence of the dosage regimen on the therapeutic activity of penicillin G. J Pharmacol Exp Ther 96: 258-268.
23. Craig WA, Ebert SC. 1992. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 36: 2577-2583. http://dx.doi.org /10.1128/AAC.36.12.2577.
24. Bakker-Woudenberg IA, van den Berg JC, Fontijne P, Michel MF. 1984. Efficacy of continuous versus intermittent administration of penicillinGin Streptococcus pneumoniae pneumonia in normal and immunodeficient rats. Eur J Clin Microbiol 3: 131-135. http://dx.doi.org/10.1007/BF02014330.
25. Craig WA, Gudmundsson S. 1991. Postantibiotic effect, p 403-431. In Lorian V (ed), Antibiotics in laboratory medicine, 3rd ed. The Williams &Wilkins Co., Baltimore, MD.
26. Leggett JE, Fantin B, Ebert S, Totsuka B, Vogelman B, Calame W, Mattie H, Craig WA. 1989. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 159: 281-292. http://dx.doi.org/10.1093/infdis/159.2.281.
27. Roosendaal R, Bakker-Woudenberg IA, van den Berg JC, Michel MF. 1985. Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J Infect Dis 152: 373-378. http://dx.doi.org/10.1093/infdis /152.2.373.
28. Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Michel MF. 1986. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 30: 403-408. http://dx.doi.org/10.1128/AAC.30.3.403.
29. Mordenti JJ, Quintiliani R, Nightingale CH. 1985. Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model. J Antimicrob Chemother 15(Suppl A):312-313.
30. White CA, Toothaker RD. 1985. Influence of ampicillin elimination half-life on in-vitro bactericidal effect. J Antimicrob Chemother 15(Suppl A):257-260. http://dx.doi.org/10.1093/jac/15.2.257,10.1093/jac/15.suppl_A.257.
31. Mouton JW, den Hollander JG. 1994. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 38: 931-936. http://dx.doi.org/10.1128/AAC.38.5.931.
32. Keil S, Wiedemann B. 1997. Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model. Antimicrob Agents Chemother 41: 1215-1219.
33. Bowker KE, Holt HA, Lewis RJ, Reeves DS, MacGowan AP. 1998. Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans. J Antimicrob Chemother 42: 461-467. http://dx.doi.org/10.1093/jac/42.4.461.
34. Flückiger U, Segessenmann C, Gerber AU. 1991. Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model. Antimicrob Agents Chemother 35: 1905-1910. http://dx.doi.org/10.1128/AAC.35.9.1905.
35. Fuentes F, Martín MM, Izquierdo J, Gomez-Lus ML, Prieto J. 1995. In vivo and in vitro study of several pharmacodynamic effects of meropenem. Scand J Infect Dis 27: 469-474. http://dx.doi.org/10.3109/00365549509047048.
36. Elkhaïli H, Peter JD, Pompei D, Levless-Than-Or-Eq Slanteque D, Linger L, Salmon Y, Salmon J, Monteil H. 1998. Pharmacokinetics in vivo and pharmacodynamics ex vivo/in vitro of meropenem and cefpirome in the Yucatan micropig model: continuous infusion versus intermittent injection. Clin Microbiol Infect 4: 18-26. http://dx.doi.org/10.1111/j.1469-0691.1998.tb00329.x.
37. MacGowan AP, Bowker KE. 1998. Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet 35: 391-402. http://dx.doi.org/10.2165/00003088-199835050-00004.
38. Leder K, Turnidge JD, Korman TM, Grayson ML. 1999. The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis. J Antimicrob Chemother 43: 113-118. http://dx.doi.org/10.1093/jac/43.1.113.
39. Mouton JW, Horrevorts AM, Mulder PG, Prens EP, Michel MF. 1990. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother 34: 2307-2311. http://dx.doi.org/10.1128/AAC.34.12.2307.
40. Vinks AA, Brimicombe RW, Heijerman HG, Bakker W. 1997. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother 40: 125-133. http://dx.doi.org/10.1093/jac/40.1.125.
41. Kuzemko J, Crawford C. 1989. Continuous infusion of ceftazidime in cystic fibrosis. Lancet ii:385.
42. Daenen S, Erjavec Z, Uges DR, De Vries-Hospers HG, De Jonge P, Halie MR. 1995. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis 14: 188-192. http://dx.doi.org/10.1007/BF02310354.
43. Benko AS, Cappelletty DM, Kruse JA, Rybak MJ. 1996. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 40: 691-695.
44. Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ. 1999. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 43: 309-311. http://dx.doi.org/10.1093/jac/43.2.309.
45. Nicolau DP, McNabb J, Lacy MK, Li J, Quintiliani R, Nightingale CH. 1999. Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumonia. Clin Drug Invest 18: 133-139. http://dx.doi.org/10.2165/00044011-199918020-00006.
46. Nicolau DP, Lacy MK, McNabb J, Quintiliani R, Nightingale CH. 1998. Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumonia. Infect Dis Clin Pract 8: 45-49.
47. Thalhammer F, Traunmüller F, El Menyawi I, Frass M, Hollenstein UM, Locker GJ, Stoiser B, Staudinger T, Thalhammer-Scherrer R, Burgmann H. 1999. Continuous infusion versus intermittent adminis-tration of meropenem in critically ill patients. J Antimicrob Chemother 43: 523-527. http://dx.doi.org/10.1093/jac/43.4.523.
48. Bodey GP, Ketchel SJ, Rodriguez V. 1979. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 67: 608-616. http://dx.doi.org/10.1016/0002-9343(79)90242-0.
49. Lagast H, Meunier-Carpentier F, Klastersky J. 1983. Treatment of gram-negative bacillary septicemia with cefoperazone. Eur J Clin Microbiol 2: 554-558. http://dx.doi.org/10.1007/BF02016564.
50. Dunning J, Roberts J. 2015. Continuous infusion of beta-lactam antibiotics to treat severe sepsis: a waste of time or worth the hassle? Br J Hosp Med (Lond) 76:310. http://dx.doi.org/10.12968/hmed.2015.76.5.310.
51. De Waele JJ, Lipman J, Carlier M, Roberts JA. 2015. Subtleties in practical application of prolonged infusion of β-lactam antibiotics. Int J Antimicrob Agents 45: 461-463. http://dx.doi.org/10.1016/j.ijantimicag.2015.01.007.
52. Roberts JA, Kirkpatrick CM, Lipman J. 2011. Monte Carlo simulations:maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother 66: 227-231. http://dx.doi.org/10.1093/jac/dkq449.
53. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. 2008. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 36: 1089-1096. http://dx.doi.org/10.1097/CCM.0b013e3181691b99.
54. Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB. 2009. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients. Ann Pharmacother 43: 1747-1754. http://dx.doi.org/10.1345/aph.1M304.
55. George JM, Towne TG, Rodvold KA. 2012. Prolonged infusions of β-lactam antibiotics: implication for antimicrobial stewardship. Pharmacotherapy 32: 707-721. http://dx.doi.org/10.1002/j.1875-9114.2012.01157.x.
56. Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, Pepe J, Kuti JL. 2010. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 25: 69-77. http://dx.doi.org/10.1016/j.jcrc.2009.02.014.
57. Buijk SL, Gyssens IC, Mouton JW, Van Vliet A, Verbrugh HA, Bruining HA. 2002. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother 49: 121-128. http://dx.doi.org/10.1093/jac/49.1.121.
58. Roberts JA, Boots R, Rickard CM, Thomas P, Quinn J, Roberts DM, Richards B, Lipman J. 2007. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 59: 285-291.
59. Van Zanten AR, Oudijk M, Nohlmans-Paulssen MK, van der Meer YG, Girbes AR, Polderman KH. 2007. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/ pharmacodynamics, bacterial susceptibility and clinical efficacy. Br J Clin Pharmacol 63: 100-109. http://dx.doi.org/10.1111/j.1365-2125.2006.02730.x.
60. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sörgel F. 2007. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenemcilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 51: 3304-3310. http://dx.doi.org/10.1128/AAC.01318-06.
61. Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, Fazeli MR. 2006. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 28: 122-127. http://dx.doi.org/10.1016/j.ijantimicag.2006.02.020.
62. Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D, Dana A. 2006. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intraabdominal infection. Antimicrob Agents Chemother 50: 3556-3561. http://dx.doi.org/10.1128/AAC.50.2.556-564.2006.
63. Georges B, Conil JM, Cougot P, Decun JF, Archambaud M, Seguin T, Chabanon G, Virenque C, Houin G, Saivin S. 2005. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther 43: 360-369. http://dx.doi.org/10.5414/CPP43360.
64. Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD. 2005. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents 25: 62-67. http://dx.doi.org/10.1016/j.ijantimicag.2004.08.012.
65. Lubasch A, Lück S, Lode H, Mauch H, Lorenz J, Bölcskei P, Welte T, COPD Study Group. 2003. Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis. J Antimicrob Chemother 51: 659-664. http://dx.doi.org/10.1093/jac/dkg111.
66. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH. 2001. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 17: 497-504. http://dx.doi.org/10.1016/S0924-8579(01)00329-6.
67. Hanes SD, Wood GC, Herring V, Croce MA, Fabian TC, Pritchard E, Boucher BA. 2000. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 179: 436-440. http://dx.doi.org/10.1016/S0002-9610(00)00388-3.
68. Angus BJ, Smith MD, Suputtamongkol Y, Mattie H, Walsh AL, Wuthiekanun V, Chaowagul W, White NJ. 2000. Pharmacokineticpharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 50: 184-191. http://dx.doi.org/10.1111/j.1365-2125.2000.00179.x.
69. Lodise TP, Jr, Lomaestro B, Drusano GL. 2007. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extendedinfusion dosing strategy. Clin Infect Dis 44: 357-363. http://dx.doi.org/10.1086/510590.
70. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. 2002. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 22: 471-483. http://dx.doi.org/10.1592/phco.22.7.471.33665.
71. Patel GW, Patel N, Lat A, Trombley K, Enbawe S, Manor K, Smith R, Lodise TP, Jr. 2009. Outcomes of extended infusion piperacillin/ tazobactam for documented Gram-negative infections. Diagn Microbiol Infect Dis 64: 236-240. http://dx.doi.org/10.1016/j.diagmicrobio.2009.03.002.
72. Esterly JS, Wagner J, McLaughlin MM, Postelnick MJ, Qi C, Scheetz MH. 2012. Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification. Antimicrob Agents Chemother 56: 4885-4890. http://dx.doi.org/10.1128/AAC.06365-11.
73. Lee GC, Liou H, Yee R, Quan CF, Neldner K. 2012. Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients. Clin Ther 34: 2297-2300. http://dx.doi.org/10.1016/j.clinthera.2012.11.005.
74. Yost RJ, Cappelletty DM, RECEIPT Study Group. 2011. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study. Pharmacotherapy 31: 767-775. http://dx.doi.org/10.1592/phco.31.8.767.
75. Kollef MH, Chastre J, Clavel M, Restrepo MI, Michiels B, Kaniga K, Cirillo I, Kimko H, Redman R. 2012. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 16: R218. http://dx.doi.org/10.1186/cc11862.
76. Arnold HM, Hollands JM, Skrupky LP, Smith JR, Juang PH, Hampton NB, McCormick S, Reichley RM, Hoban A, Hoffmann J, Micek ST, Kollef MH. 2013. Prolonged infusion antibiotics for suspected gramnegative infections in the ICU: a before-after study. Ann Pharmacother 47: 170-180. http://dx.doi.org/10.1345/aph.1R523.
77. Bauer KA, West JE, O’Brien JM, Goff DA. 2013. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 57: 2907-2912. http://dx.doi.org/10.1128/AAC.02365-12.
78. Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. 2006. Meropenem by continuous versus intermittent infusion in ventilatorassociated pneumonia due to gram-negative bacilli. Ann Pharmacother 40: 219-223. http://dx.doi.org/10.1345/aph.1G467.
79. Lorente L, Jimenez A, Palmero S, Jimenez JJ, Iribarren JL, Santana M, Martin MM, Mora ML. 2007. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospec-tive, nonrandomized, open-label, historical chart review. Clin Ther 29: 2433-2439. http://dx.doi.org/10.1016/j.clinthera.2007.11.003.
80. Lorente L, Jimenez A, Martin MM, Iribarren JL, Jimenez JJ, Mora ML. 2009. Clinical cure of ventilator-associated pneumonia treated with piperacillin/ tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 33: 464-468. http://dx.doi.org/10.1016/j.ijantimicag.2008.10.025.
81. Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova T, Pradl R, Kasal E. 2012. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 16: R113. http://dx.doi.org/10.1186/cc11405.
82. Laterre PF, Wittebole X, Van de Velde S, Muller AE, Mouton JW, Carryn S, Tulkens PM, Dugernier T. 2015. Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. J Antimicrob Chemother 70: 891-898. http://dx.doi.org/10.1093/jac/dku465.
83. Dow R, Rose W, Fox B. 2011. Retrospective study of prolonged versus intermittent infusion piperacillin-tazobactam and meropenem in intensive care unit patients at an academic medical center. Infect Dis Clin Pract 19: 413-417. http://dx.doi.org/10.1097/IPC.0b013e31822e9bf5.
84. Itabashi S. 2007. Clinical efficacy of prolonged (4 hour) drip infusion of meropenem against severe pneumonia. Jpn J Antibiot 60: 161-170.
85. Wang D. 2009. Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrugresistant Acinetobacter baumannii. Int J Antimicrob Agents 33: 290-291. http://dx.doi.org/10.1016/j.ijantimicag.2008.09.012.
86. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Lipman J. 2013. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 56: 236-244. http://dx.doi.org/10.1093/cid/cis856.
87. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Starr T, Paul SK, Lipman J. 2015. A multicenter randomized trial of continuous versus intermittent β-lactam infusion in severe sepsis. Am J Respir Crit Care Med 192: 1298-1305. http://dx.doi.org/10.1164/rccm.201505-0857OC.
88. Abdul-Aziz MH, Dulhunty JM, Bellomo R, Lipman J, Roberts JA. 2012. Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care 2: 37. http://dx.doi.org/10.1186/2110-5820-2-37.
89. Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME. 2005. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 5: 581-589. http://dx.doi.org/10.1016/S1473-3099(05)70218-8.
90. Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J. 2007. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 30: 111-118.
91. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. 2009. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 37: 2071-2078. http://dx.doi.org/10.1097/CCM.0b013e3181a0054d.
92. Perrott J, Mabasa VH, Ensom MH. 2010. Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamics principles: a qualitative systematic review. Ann Pharmacother 44: 557-564. http://dx.doi.org/10.1345/aph.1M339.
93. Tamma PD, Putcha N, Suh YD, Van Arendonk KJ, Rinke ML. 2011. Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions?Ameta-analysis and systematic review of randomized, controlled trials. BMC Infect Dis 11: 181. http://dx.doi.org /10.1186/1471-2334-11-181.
94. Mah GT, Mabasa VH, Chow I, Ensom MH. 2012. Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review. Ann Pharmacother 46: 265-275. http://dx.doi.org/10.1345/aph.1Q378.
95. Smuszkiewicz P, Szałek E, Tomczak H, Grzeoekowiak E. 2013. Continuous infusion of antibiotics in critically ill patients. Curr Clin Pharmacol 8: 13-24. http://dx.doi.org/10.2174/1574884711308010004.
96. Shiu J, Wang E, Tejani AM, Wasdell M. 2013. Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections. Cochrane Database Syst Rev 3: CD008481. http://dx.doi.org /10.1002/14651858.CD008481.pub2.
97. Korbila IP, Tansarli GS, Karageorgopoulos DE, Vardakas KZ, Falagas ME. 2013. Extended or continuous versus short-term intravenous infusion of cephalosporins: a meta-analysis. Expert Rev Anti Infect Ther 11: 585-595. http://dx.doi.org/10.1586/eri.13.44.
98. MacVane SH, Kuti JL, Nicolau DP. 2014. Prolonging β-lactam infusion: a review of the rationale and evidence, and guidance for implementation. Int J Antimicrob Agents 43: 105-113. http://dx.doi.org/10.1016/j.ijantimicag.2013.10.021.
99. Teo J, Liew Y, Lee W, Kwa AL. 2014. Prolonged infusion versus intermittent boluses of β-lactam antibiotics for treatment of acute infections: a meta-analysis. Int J Antimicrob Agents 5: 403-411.
100. Yang H, Zhang C, Zhou Q, Wang Y, Chen L. 2015. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis. PLoS One 10: e0116769 http://dx.doi.org /10.1371/journal.pone.0116769.
101. Burgess SV, Mabasa VH, Chow I, Ensom MH. 2015. Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review. Ann Pharmacother 49: 311-322. http://dx.doi.org/10.1177/1060028014564179.
102. Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, Bellomo R, Lipman J. 14 March 2016. Continuous versus intermittent beta-lactam infusion in severe sepsis: a meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med http://dx.doi.org/10.1164/rccm.201601-0024OC.
103. Dellit TH, Owens RC, McGowan JE, Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America. 2007. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44: 159-177. http://dx.doi.org/10.1086/510393.
104. George JM, Colton BJ, Rodvold KA. 2012. National survey on continuous and extended infusions of antibiotics. Am J Health Syst Pharm 69: 1895-1904. http://dx.doi.org/10.2146/ajhp110562.
105. Buyle FM, Decruyenaere J, De Waele J, Tulkens PM, Van Audenrode T, Depuydt P, Claeys G, Robays H, Vogelaers D. 2013. A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals. Eur J Clin Microbiol Infect Dis 32: 763-768. http://dx.doi.org/10.1007/s10096-012-1803-7.
106. Sloots TP, Nissen MD, Ginn AN, Iredell JR. 2015. Rapid identification of pathogens using molecular techniques. Pathology 47: 191-198. http://dx.doi.org/10.1097/PAT.0000000000000241.
107. Spaargaren J, van Boven CP, Voorn GP. 1998. Effectiveness of resins in neutralizing antibiotic activities in bactec plus Aerobic/F culture medium. J Clin Microbiol 36: 3731-3713.
108. Viganò EF, Vasconi E, Agrappi C, Clerici P, Melloni P. 2004. Use of simulated blood cultures for antibiotic effect on time to detection of the two blood culture systems BacT/ALERT and BACTEC 9240. New Microbiol 27: 235-248.
109. Zadroga R, Williams DN, Gottschall R, Hanson K, Nordberg V, Deike M, Kuskowski M, Carlson L, Nicolau DP, Sutherland C, Hansen GT. 2013. Comparison of 2 blood culture media shows significant differences in bacterial recovery for patients on antimicrobial therapy. Clin Infect Dis 56: 790-797. http://dx.doi.org/10.1093/cid/cis1021.
110. Mitteregger D, Barousch W, Nehr M, Kundi M, Zeitlinger M, Makristathis A, Hirschl AM. 2013. Neutralization of antimicrobial substances in new BacT/Alert FA and FN Plus blood culture bottles. J Clin Microbiol 51: 1534-1540. http://dx.doi.org/10.1128/JCM.00103-13.
111. Fiori B, D’Inzeo T, Di Florio V, De Maio F, De Angelis G, Giaquinto A, Campana L, Tanzarella E, Tumbarello M, Antonelli M, Sanguinetti M, Spanu T. 2014. Performance of two resin-containing blood culture media in detection of bloodstream infections and in direct matrixassisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) broth assays for isolate identification: clinical comparison of the BacT/Alert Plus and Bactec Plus systems. J Clin Microbiol 52: 3558-3567. http://dx.doi.org/10.1128/JCM.01171-14.
112. Owens RC, Jr, Shorr AF. 2009. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharm 66: S23-30. http://dx.doi.org/10.2146/090087d.
113. Bobenchik AM, Deak E, Hindler JA, Charlton CL, Humphries RM. 2015. Performance of Vitek 2 for antimicrobial susceptibility testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI breakpoints. J Clin Microbiol 53: 816-823. http://dx.doi.org/10.1128/JCM.02697-14.
114. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. CLSI document M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
115. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
116. Tamma PD, Turnbull AE, Milstone AM, Hsu AJ, Carroll KC, Cosgrove SE. 2012. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia? Clin Infect Dis 55: 799-806. http://dx.doi.org/10.1093/cid/cis545.
117. Hombach M, Bloemberg GV, Böttger EC. 2012. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli. J Antimicrob Chemother 67: 622-632. http://dx.doi.org/10.1093/jac/dkr524.
118. Mohr JF, Wanger A, Rex JH. 2004. Pharmacokinetic/ pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis 48: 125-130. http://dx.doi.org/10.1016/j.diagmicrobio.2003.09.010.
119. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
120. Becton, Dickinson and Company. 2016. BD Phoenix automated microbiology system. http://www.bd.com/ds/productCenter/IS-Phoenix.asp. Becton, Dickinson and Company, Franklin Lakes, NJ. Accessed 27 December 2015.
121. bioMérieux. 2016. Bacterial identification and antibiotic susceptibility testing. VITEK 2. http://www.biomerieux.com/en/bacterial-identification-antibiotic-susceptibility-testing-vitek-2. bioMérieux, Marcy-l’Étoile, France. Accessed 27 December 2015.
122. Beckman Coulter. 2016. Microbiology systems. https://www.beckmancoulter.com/wsrportal/wsr/diagnostics/clinical-products /microbiology/microbiology-systems/index.htm. Beckman Coulter, Brea, CA. Accessed 27 December 2015.
123. Baker CN, Stocker SA, Culver DM, Thornsberry C. 1991. Comparison of the E-test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol 29: 533-538.
124. Ghazi IM, Crandon JL, Lesho EP, McGann P, Nicolau DP. 2015. Efficacy of humanized high-dose meropenem, cefepime, and levofloxacin against Enterobacteriaceae isolates producing Verona integronencoded metallo-β-lactamase (VIM) in a murine thigh infection model. Antimicrob Agents Chemother 59: 7145-7147. http://dx.doi.org/10.1128/AAC.00794-15.
125. Zmarlicka MT, Nailor MD, Nicolau DP. 2015. Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics. Infect Drug Resist 8: 297-309. http://dx.doi.org/10.2147/IDR.S39186.
126. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL. 2010. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing theKPCcarbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 54: 804-810. http://dx.doi.org/10.1128/AAC.01190-09.
127. Wiskirchen DE, Koomanachai P, Nicasio AM, Nicolau DP, Kuti JL. 2011. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Antimicrob Agents Chemother 55: 1420-1427. http://dx.doi.org/10.1128/AAC.01253-10.
128. BioFire Diagnostics. 2016. Guidelines for laboratory verification of performance of the FilmArray blood culture identification (BCID) panel. http://www.biofiredx.com/wp-content/uploads/2016/03/TN-FLM1-PRT-0137-04-Guidelines-for-Laboratory-Verification-of-Performance-of-the-FilmArray-Blood-Culture-Identification-Panel.pdf. BioFire Diagnostics, Salt Lake City, UT. Accessed 22 June 2016.
129. Nanosphere Inc. 2016. Gram-negative blood culture test. http://www.nanosphere.us/products/gram-negative-blood-culture-test. Nanosphere Inc., Northbrook, IL. Accessed 2 March 2016.
130. Cepheid. 2016. Cepheid | Xpert Carba-R. http://www.cepheid.com/en/ cepheid-solutions-uk/clinical-ivd-tests/healthcare-associated-infections /xpert-carbar. Cepheid, Sunnyvale, CA. Accessed 2 March 2016.
131. Gonçalves-Pereira J, Póvoa P. 2011. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care 15: R206. http://dx.doi.org/10.1186/cc10441.
132. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA. 2012. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 142: 30-39. http://dx.doi.org/10.1378/chest.11-1671.
133. Lamoth F, Buclin T, Pascual A, Vora S, Bolay S, Decosterd LA, Calandra T, Marchetti O. 2010. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother 54: 4360-4367. http://dx.doi.org/10.1128/AAC.01595-08.
134. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, DALI Study. 2014. DALI: defining antibiotic levels in intensive care unit patients: are currentβ-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58: 1072-1083. http://dx.doi.org/10.1093/cid/ciu027.
135. Patel BM, Paratz J, See NC, Muller MJ, Rudd M, Paterson D, Briscoe SE, Ungerer J, McWhinney BC, Lipman J, Roberts JA. 2012. Therapeutic drug monitoring of beta-lactam antibiotics in burns patients-a one-year prospective study. Ther Drug Monit 34: 160-164. http://dx.doi.org/10.1097/FTD.0b013e31824981a6.
136. Aubert G, Carricajo A, Coudrot M, Guyomarc’h S, Auboyer C, Zeni F. 2010. Prospective determination of serum ceftazidime concentrations in intensive care units. Ther Drug Monit 32: 517-519. http://dx.doi.org/10.1097/FTD.0b013e3181e60ca6.
137. Wong G, Brinkman A, Benefield RJ, Carlier M, De Waele JJ, El Helali N, Frey O, Harbarth S, Huttner A, McWhinney B, Misset B, Pea F, Preisenberger J, Roberts MS, Robertson TA, Roehr A, Sime FB, Taccone FS, Ungerer JP, Lipman J, Roberts JA. 2014. An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 69: 1416-1423. http://dx.doi.org/10.1093/jac/dkt523.
138. Huttner A, Harbarth S, Hope WW, Lipman J, Roberts JA. 2015. Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother 70: 3178-3183. http://dx.doi.org/10.1093/jac/dkv201.
139. Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA. 2012. Does beta-Lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care 2: 35. http://dx.doi.org/10.1186/2110-5820-2-35.
140. Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J. 2010. Therapeutic drug monitoring of betalactams in critically ill patients: proof of concept. Int J Antimicrob Agents 36: 332-339. http://dx.doi.org/10.1016/j.ijantimicag.2010.06.008.
141. Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N. 2013. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet 52: 9-22. http://dx.doi.org/10.1007/s40262-012-0020-y.
142. Kuti JL, Moss KM, Nicolau DP, Knauft RF. 2004. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy 24: 1641-1645. http://dx.doi.org/10.1592/phco.24.16.1641.50960.